ArticlePituitary2025
Neurocognitive evaluation of patients with non-functioning pituitary adenoma.
Article in Pituitary, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveWe aimed to evaluate the neurocognitive functions of patients with non-functioning pituitary adenoma (NFPA).
methodsEighty patients with NFPA and 80 control subjects matched for age, sex, body mass index (BMI) and educational status were included. The Beck Depression Inventory (BDI) for depression, the Cognitive Failures Questionnaire (CFQ), the Prospective and Retrospective Memory Questionnaire (PRMQ) and the Memory Functioning Questionnaire (MFQ) for assessing cognitive functions were administered.
resultsNFPA patients had significantly higher CFQ and PRMQ scores than controls (p < 0.05), reflecting greater cognitive failure and memory impairment. MFQ subscales revealed increased general forgetfulness, severity of forgetting, and impaired retrospective function in NFPA patients (p < 0.05). Name recall was worse among those who underwent surgery or received radiotherapy/gamma-knife treatment. Social dysfunction was more common in patients with secondary adrenal insufficiency (p = 0.038), higher corticosteroid doses (p < 0.05), and greater concentration problems (p = 0.036). Hypogonadism was associated with impaired name recall (p = 0.040) and social failure (p = 0.024). Name recall declined as postoperative time increased (p = 0.029). Low IGF-1 levels were linked to worse prospective memory, more frequent forgetfulness, and greater social dysfunction (p = 0.042).
conclusionOur findings suggest that the cognitive impairments observed in patients with NFPA may result not only from pituitary dysfunction but also from treatment approaches such as reoperations, gamma-knife or radiotherapy. These results highlight the importance of comprehensive neurocognitive assessment and long-term follow-up in the management of NFPA patients, particularly those with hormonal deficiencies or who undergo repeated interventions.
Indexed as
Identifiers
41006692What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.